Sponsors (4)
Introduced May 1, 2025 by Thomas Roland Tillis · Last progress May 1, 2025
The bill trades clearer, broader eligibility (encouraging patents for machine/computer-based and engineered-biological inventions) and faster eligibility decisions for increased risk of broader software and other patents, higher licensing costs, reduced judicial filtering of weak claims, and continued uncertainty over borderline cases.
Researchers, inventors, and the public gain clearer, more predictable patent-eligibility rules for inventions (especially computer- and machine-implemented claims), reducing uncertainty when preparing and filing patent applications.
Tech companies, startups, and investors can obtain patents for a wider range of machine- or computer-dependent inventions and many useful processes, which may encourage investment and commercialization of tech innovations.
Biotech and pharmaceutical innovators retain eligibility for engineered, purified, enriched, isolated, or otherwise altered biological materials and processed natural substances, protecting many diagnostic, therapeutic, and processed-material inventions.
Consumers and businesses could face higher costs because broader patent eligibility (especially for software- and machine-assisted technologies) may produce more patents that require licensing or raise barriers to competition.
Preventing courts from relying on §§102, 103, and 112 to inform eligibility reduces judicial flexibility to weed out weak or improper claims early, likely increasing USPTO and court workload and risking issuance of broader patents with less substantive vetting.
Inventors and small firms face greater litigation risk and uncertainty because the bill leaves fuzzy lines—e.g., when a business or social process becomes patentable if implemented with a machine, or what it means for a computer to be "necessary to practically perform" an invention.
Based on analysis of 4 sections of legislative text.
Eliminates judicial eligibility exceptions, makes most useful inventions eligible while excluding pure math, purely mental acts, unmodified human genes/natural materials, and mainly economic/social/business/artistic processes.
Rewrites patent-eligibility law to eliminate judicially created exceptions and restore broad eligibility for any useful process, machine, manufacture, or composition of matter (and useful improvements), while listing specific exclusions. It narrows what courts may treat as ineligible (pure math, purely mental processes, unmodified human genes and natural materials, and certain economic/social/business/artistic processes) and instructs that eligibility must be assessed for the claimed invention as a whole without using novelty, nonobviousness, or written‑description rules as eligibility gates.